Search results
Results from the WOW.Com Content Network
HC Wainwright analyst Andrew Fein maintains Neurocrine Biosciences with a Buy and lowers the price target from $190 to $185. Price Action: NBIX stock is down 191% at $121.98 at the last check on ...
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, ... and the repurchase of approximately 2 million shares for $240.5 million under a $300 million share repurchase program. ...
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. [1] It is headquartered in San Diego, California , and led by CEO Kevin Gorman. [ 3 ] Neurocrine develops treatments for neurological and endocrine-related diseases and disorders.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NBI-1117568 (former developmental code name HTL-0016878) is an investigational antipsychotic drug for schizophrenia that was out-licensed Nexera Pharma in to Neurocrine Biosciences, a United States-based pharmaceutical company. [1] [2] It is administered orally. [3] [4]
For premium support please call: 800-290-4726 more ways to reach us
Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in ...